Landscape Capital Management L.L.C. Invests $331,000 in Enovis Co. (NYSE:ENOV)

Landscape Capital Management L.L.C. purchased a new stake in shares of Enovis Co. (NYSE:ENOV) during the third quarter, Holdings Channel reports. The institutional investor purchased 7,696 shares of the company’s stock, valued at approximately $331,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Quest Partners LLC bought a new position in Enovis in the 3rd quarter valued at $741,000. Mutual of America Capital Management LLC boosted its stake in Enovis by 5.6% during the third quarter. Mutual of America Capital Management LLC now owns 30,183 shares of the company’s stock valued at $1,299,000 after buying an additional 1,604 shares during the period. Natixis Advisors LLC purchased a new position in Enovis during the third quarter worth about $546,000. Royce & Associates LP increased its stake in Enovis by 16.8% in the 3rd quarter. Royce & Associates LP now owns 2,403,685 shares of the company’s stock worth $103,479,000 after acquiring an additional 346,317 shares during the last quarter. Finally, Oppenheimer Asset Management Inc. raised its holdings in shares of Enovis by 19.8% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 11,829 shares of the company’s stock valued at $509,000 after acquiring an additional 1,953 shares in the last quarter. 98.45% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. JPMorgan Chase & Co. dropped their target price on shares of Enovis from $53.00 to $50.00 and set a “neutral” rating for the company in a research report on Thursday, August 8th. Evercore ISI cut their target price on shares of Enovis from $62.00 to $58.00 and set an “outperform” rating for the company in a research report on Tuesday, October 1st. Needham & Company LLC restated a “buy” rating and set a $65.00 price target on shares of Enovis in a research report on Thursday, November 7th. Finally, JMP Securities started coverage on Enovis in a research note on Thursday, October 3rd. They set an “outperform” rating and a $62.00 price target for the company. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, Enovis presently has an average rating of “Moderate Buy” and a consensus price target of $67.00.

Enovis Trading Up 1.1 %

Enovis stock opened at $46.67 on Monday. Enovis Co. has a one year low of $38.27 and a one year high of $65.03. The business’s fifty day moving average is $42.70 and its 200 day moving average is $44.96. The stock has a market capitalization of $2.61 billion, a PE ratio of -21.31 and a beta of 1.91. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.27 and a quick ratio of 1.12.

Enovis (NYSE:ENOV) last announced its earnings results on Wednesday, November 6th. The company reported $0.73 earnings per share for the quarter, beating analysts’ consensus estimates of $0.62 by $0.11. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. The business had revenue of $505.22 million during the quarter, compared to analyst estimates of $504.44 million. The company’s quarterly revenue was up 21.0% compared to the same quarter last year. During the same period in the previous year, the business earned $0.56 EPS. On average, sell-side analysts predict that Enovis Co. will post 2.79 EPS for the current year.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.